JP2020516590A - 膀胱癌の治療方法 - Google Patents

膀胱癌の治療方法 Download PDF

Info

Publication number
JP2020516590A
JP2020516590A JP2019553212A JP2019553212A JP2020516590A JP 2020516590 A JP2020516590 A JP 2020516590A JP 2019553212 A JP2019553212 A JP 2019553212A JP 2019553212 A JP2019553212 A JP 2019553212A JP 2020516590 A JP2020516590 A JP 2020516590A
Authority
JP
Japan
Prior art keywords
individual
oncolytic virus
administered
bladder
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019553212A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020516590A5 (https=
Inventor
アーサー クアン，
アーサー クアン，
Original Assignee
コールド ジェネシス， インコーポレイテッド
コールド ジェネシス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コールド ジェネシス， インコーポレイテッド, コールド ジェネシス， インコーポレイテッド filed Critical コールド ジェネシス， インコーポレイテッド
Publication of JP2020516590A publication Critical patent/JP2020516590A/ja
Publication of JP2020516590A5 publication Critical patent/JP2020516590A5/ja
Priority to JP2022136745A priority Critical patent/JP7597384B2/ja
Priority to JP2024006788A priority patent/JP2024028541A/ja
Priority to JP2026000350A priority patent/JP2026042875A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2019553212A 2017-04-14 2018-04-13 膀胱癌の治療方法 Pending JP2020516590A (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022136745A JP7597384B2 (ja) 2017-04-14 2022-08-30 膀胱癌の治療方法
JP2024006788A JP2024028541A (ja) 2017-04-14 2024-01-19 膀胱癌の治療方法
JP2026000350A JP2026042875A (ja) 2017-04-14 2026-01-05 膀胱癌の治療方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762485805P 2017-04-14 2017-04-14
US62/485,805 2017-04-14
US201762500729P 2017-05-03 2017-05-03
US62/500,729 2017-05-03
PCT/US2018/027549 WO2018191654A1 (en) 2017-04-14 2018-04-13 Methods of treating bladder cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022136745A Division JP7597384B2 (ja) 2017-04-14 2022-08-30 膀胱癌の治療方法

Publications (2)

Publication Number Publication Date
JP2020516590A true JP2020516590A (ja) 2020-06-11
JP2020516590A5 JP2020516590A5 (https=) 2021-06-17

Family

ID=63792825

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019553212A Pending JP2020516590A (ja) 2017-04-14 2018-04-13 膀胱癌の治療方法
JP2022136745A Active JP7597384B2 (ja) 2017-04-14 2022-08-30 膀胱癌の治療方法
JP2024006788A Pending JP2024028541A (ja) 2017-04-14 2024-01-19 膀胱癌の治療方法
JP2026000350A Pending JP2026042875A (ja) 2017-04-14 2026-01-05 膀胱癌の治療方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022136745A Active JP7597384B2 (ja) 2017-04-14 2022-08-30 膀胱癌の治療方法
JP2024006788A Pending JP2024028541A (ja) 2017-04-14 2024-01-19 膀胱癌の治療方法
JP2026000350A Pending JP2026042875A (ja) 2017-04-14 2026-01-05 膀胱癌の治療方法

Country Status (9)

Country Link
US (4) US11338003B2 (https=)
EP (2) EP4599893A3 (https=)
JP (4) JP2020516590A (https=)
KR (1) KR102949236B1 (https=)
CN (1) CN110573624A (https=)
AU (1) AU2018251987B2 (https=)
ES (1) ES3030923T3 (https=)
PL (1) PL3610026T3 (https=)
WO (1) WO2018191654A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017156349A1 (en) 2016-03-10 2017-09-14 Cold Genesys, Inc. Methods of treating solid or lymphatic tumors by combination therapy
EP4599893A3 (en) 2017-04-14 2025-11-05 CG Oncology, Inc. Cg0070 for treating bcg resistant bladder carcinoma in situ
CN111542601A (zh) * 2017-11-08 2020-08-14 国立大学法人鹿儿岛大学 确保安全并且能够有效地治疗甚至转移性癌症的、具有提供装载的免疫诱导基因的最佳表达水平的表达控制系统的肿瘤溶解性病毒(肿瘤溶解性免疫治疗)
JP7340591B2 (ja) 2018-07-11 2023-09-07 アクティム・セラピューティクス・インコーポレイテッド 遺伝子操作された免疫刺激性細菌菌株およびその使用
US20200222477A1 (en) * 2019-01-10 2020-07-16 Trizell Ltd. Method to Curtail the Progression of Non-Muscle Invasive Bladder Cancer To Muscle-Invasive Cancer
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
JP2022524951A (ja) 2019-02-27 2022-05-11 アクティム・セラピューティクス・インコーポレイテッド 腫瘍、腫瘍常在免疫細胞および腫瘍微小環境にコロニー形成するよう操作した免疫刺激性細菌
JP2023501539A (ja) 2019-11-12 2023-01-18 アクティム・セラピューティクス・インコーポレイテッド 免疫刺激細菌デリバリープラットフォーム、および治療用産物のデリバリーのためのその使用
IL300447A (en) 2020-08-12 2023-04-01 Actym Therapeutics Inc Bacteria-based ingredients that stimulate the immune system, treatments and platforms for delivering RNA
WO2023086796A2 (en) 2021-11-09 2023-05-19 Actym Therapeutics, Inc. Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment
WO2025251009A1 (en) * 2024-05-31 2025-12-04 Cg Oncology, Inc. Methods of treating bladder cancer using an oncolytic virus and a transduction-enhancing agent
WO2025251003A1 (en) * 2024-05-31 2025-12-04 Cg Oncology, Inc. Methods of treating bladder cancer using an oncolytic virus

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4590071A (en) 1984-09-25 1986-05-20 Xoma Corporation Human melanoma specific immunotoxins
US7001764B2 (en) 1995-06-27 2006-02-21 Cell Genesys, Inc. Compositions comprising tissue specific adenoviral vectors
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6432700B1 (en) 1997-03-03 2002-08-13 Cell Genesys, Inc. Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same
EP1007715A2 (en) 1997-03-03 2000-06-14 Calydon, Inc. Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same
AU2003252891B2 (en) 1998-09-10 2006-06-01 Cold Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
US6900049B2 (en) 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US6495130B1 (en) 1998-12-30 2002-12-17 Calydon, Inc. Target cell-specific adenoviral vectors containing E3 and methods of use thereof
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US7048920B2 (en) 2000-03-24 2006-05-23 Cell Genesys, Inc. Recombinant oncolytic adenovirus for human melanoma
WO2001073093A2 (en) 2000-03-24 2001-10-04 Cell Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site
US6692736B2 (en) 2000-03-24 2004-02-17 Cell Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site
EP1320599A2 (en) 2000-06-28 2003-06-25 Genetics Institute, LLC Pd-l2 molecules: pd-1 ligands and uses therefor
NZ536420A (en) 2002-04-12 2008-04-30 Medarex Inc Methods of treatment using CTLA-4 antibodies
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
US7459154B2 (en) 2002-12-26 2008-12-02 Cell Genesys, Inc. Methods and reagents for the enhancement of virus transduction in the bladder epithelium
WO2004060911A2 (en) 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
US20040197312A1 (en) 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
US20050186178A1 (en) 2003-08-28 2005-08-25 Ennist David L. Oncolytic adenoviral vectors encoding GM-CSF
US20050282280A1 (en) 2003-08-28 2005-12-22 Ennist David L Oncolytic adenoviral vectors encoding GM-CSF
AU2003265873A1 (en) 2003-08-28 2005-04-14 Cell Genesys, Inc. Oncolytic adenoviral vectors encoding gm-csf
US7473418B2 (en) 2004-03-25 2009-01-06 Cell Genesys, Inc. Pan cancer oncolytic vectors and methods of use thereof
TW200607859A (en) 2004-08-23 2006-03-01 Cell Genesys Inc Oncolytic adenoviral vectors encoding GM-CSF
US20060062764A1 (en) 2004-08-25 2006-03-23 Seshidar-Reddy Police Fiber-modified adenoviral vectors for enhanced transduction of tumor cells
DK1877090T3 (da) 2005-05-06 2014-04-14 Providence Health System Trimert ox40-immunoglobulin-fusionsprotein og fremgangsmåder til anvendelse heraf
GB0522476D0 (en) 2005-11-03 2005-12-14 Biovex Ltd Oncolytic herpes virus vectors
EP2010216A4 (en) 2006-03-24 2010-06-09 Donald L Morton MYCOBACTERIAL IMMUNOTHERAPY FOR CANCER TREATMENT
WO2007123737A2 (en) 2006-03-30 2007-11-01 University Of California Methods and compositions for localized secretion of anti-ctla-4 antibodies
US7919079B2 (en) 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
KR101523391B1 (ko) 2006-12-27 2015-05-27 에모리 유니버시티 감염 및 종양 치료를 위한 조성물 및 방법
US8840881B2 (en) 2008-08-28 2014-09-23 Aduro Gvax Inc. Methods and compositions for treating prostate cancer or inducing a humoral immune response against prostate cancer
AU2009332883B2 (en) 2008-12-22 2015-05-21 Oncos Therapeutics Oy Oncolytic adenoviral vectors and methods and uses related thereto
US9345787B2 (en) 2008-12-22 2016-05-24 Targovax Oy Adenoviral vectors and methods and uses related thereto
DK3622815T3 (da) 2009-07-08 2023-06-26 Kymab Ltd Gnavermodeller og terapeutiske molekyler
US20130243731A1 (en) 2010-09-24 2013-09-19 Oncos Therapeutics Oy Oncolytic adenoviral vectors coding for monoclonal anti-ctla-4 antibodies
US9056133B2 (en) 2011-05-25 2015-06-16 Cti-S.A. Pharmaceutical kit and method for treating cancer
WO2013112942A1 (en) 2012-01-25 2013-08-01 Dna Trix, Inc. Biomarkers and combination therapies using oncolytic virus and immunomodulation
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
AU2013296919A1 (en) 2012-07-30 2015-01-22 Alex Wah Hin Yeung Cancer vaccine comprises tumor cells, an oncolytic virus vector and/or an immune checkpoint modulator
DK2986311T3 (en) 2013-04-18 2019-02-25 Tilt Biotherapeutics Oy IMPROVED ADOPTIVE CELL THERAPY
CN106029889A (zh) 2013-11-22 2016-10-12 德那翠丝有限公司 表达免疫细胞刺激受体激动剂的腺病毒
ES2833425T3 (es) 2014-07-16 2021-06-15 Roussy Inst Gustave Combinación de virus oncolítico con moduladores de punto de control inmunitario
EP4245376A3 (en) 2014-10-14 2023-12-13 Novartis AG Antibody molecules to pd-l1 and uses thereof
CN107580501A (zh) * 2015-03-12 2018-01-12 维文蒂亚生物公司 用于靶向epcam阳性膀胱癌的给药策略
ES2994611T3 (en) 2015-10-19 2025-01-27 Cg Oncology Inc Methods of treating solid or lymphatic tumors by combination therapy
WO2017156349A1 (en) 2016-03-10 2017-09-14 Cold Genesys, Inc. Methods of treating solid or lymphatic tumors by combination therapy
EP4599893A3 (en) 2017-04-14 2025-11-05 CG Oncology, Inc. Cg0070 for treating bcg resistant bladder carcinoma in situ

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HISTORY OF CHANGE FOR STUDY:NCT01438112, [ONLINE], 2016-JUL-27, CLINICALTRIALS.GOV ARCHIVE, NCT ID:N, JPN6022019906, ISSN: 0005164467 *
J. UROL., (2016), 195, [4S], P.E142(MP13-19), JPN6022019907, ISSN: 0005164466 *

Also Published As

Publication number Publication date
US12370229B2 (en) 2025-07-29
US11338003B2 (en) 2022-05-24
KR102949236B1 (ko) 2026-04-08
AU2018251987A1 (en) 2019-12-05
US20220296658A1 (en) 2022-09-22
US20220331384A1 (en) 2022-10-20
CN110573624A (zh) 2019-12-13
EP4599893A3 (en) 2025-11-05
PL3610026T3 (pl) 2025-07-28
EP4599893A2 (en) 2025-08-13
ES3030923T3 (en) 2025-07-02
US20210085734A1 (en) 2021-03-25
JP2024028541A (ja) 2024-03-04
EP3610026A1 (en) 2020-02-19
JP7597384B2 (ja) 2024-12-10
AU2018251987B2 (en) 2024-11-28
JP2026042875A (ja) 2026-03-11
JP2022164776A (ja) 2022-10-27
EP3610026A4 (en) 2021-03-24
EP3610026B1 (en) 2025-05-14
US11596660B2 (en) 2023-03-07
NZ759184A (en) 2025-06-27
WO2018191654A1 (en) 2018-10-18
US20260014218A1 (en) 2026-01-15
KR20190134786A (ko) 2019-12-04

Similar Documents

Publication Publication Date Title
JP7597384B2 (ja) 膀胱癌の治療方法
US12090183B2 (en) Methods of treating solid or lymphatic tumors by combination therapy
JP6954648B2 (ja) 併用療法による固形腫瘍又はリンパ系腫瘍の治療方法
EP3324988B1 (en) Use of oncolytic herpes simplex virus in combination with immune checkpoint inhibitor, in the treatment of cancer
HK40022407A (en) Cg0070 for treating bcg resistant bladder carcinoma in situ
HK40022407B (en) Cg0070 for treating bcg resistant bladder carcinoma in situ
WO2026096653A1 (en) Methods of treating non-muscle invasive bladder cancer
TW202612713A (zh) 使用溶瘤病毒及轉導增強劑治療膀胱癌之方法
WO2025251014A1 (en) Methods and compositions for biomarker-guided bladder cancer therapy
HK1255016B (zh) 通过组合疗法治疗实体或淋巴肿瘤的方法
HK1255016A1 (en) Methods of treating solid or lymphatic tumors by combination therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210406

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210406

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220520

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220816

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230501

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231003